Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. News
Apellis Pharmaceuticals, Inc. Quantitative Score
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Apellis Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Apellis Pharmaceuticals, Inc. Financials
Table Compare
Compare APLS metrics with: | |||
|---|---|---|---|
Earnings & Growth | APLS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | APLS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | APLS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | APLS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Apellis Pharmaceuticals, Inc. Income
Apellis Pharmaceuticals, Inc. Balance Sheet
Apellis Pharmaceuticals, Inc. Cash Flow
Apellis Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Neutral |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Apellis Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Cedric Francois | Co-Founder, President, Chief Executive Officer & Director |
| Caroline R. Baumal | Chief Medical Officer |
| Timothy E. Sullivan | Chief Financial Officer & Treasurer |
| David O. Watson | General Counsel & Secretary |
| Pascal Deschatelets | Co-Founder & Chief Scientific Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Cedric Francois | Co-Founder, President, Chief Executive Officer & Director | 1972 | 1.39M | |
| Caroline R. Baumal | Chief Medical Officer | 1967 | 1.03M | |
| Timothy E. Sullivan | Chief Financial Officer & Treasurer | Male | 1971 | 797.46K |
| David O. Watson | General Counsel & Secretary | Male | 1973 | 740.11K |
| Pascal Deschatelets | Co-Founder & Chief Scientific Officer | 1970 | 688.06K |
Apellis Pharmaceuticals, Inc. Insider Trades
| Date | 27 Feb |
| Name | Dolsten Mikael |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 14312 |
| Date | 27 Feb |
| Name | Dolsten Mikael |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 24135 |
| Date | 2 Mar |
| Name | Dolsten Mikael |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 11 Feb |
| Name | DeLong Mark Jeffrey |
| Role | Chief Business & Strat Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 368 |
| Date | 3 Feb |
| Name | Francois Cedric |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 8840 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 Feb | Dolsten Mikael | Director | Acquired | A-Award | 14312 |
| 27 Feb | Dolsten Mikael | Director | Acquired | A-Award | 24135 |
| 2 Mar | Dolsten Mikael | Director | Disposed | 0 | |
| 11 Feb | DeLong Mark Jeffrey | Chief Business & Strat Officer | Disposed | S-Sale | 368 |
| 3 Feb | Francois Cedric | Chief Executive Officer | Acquired | M-Exempt | 8840 |